Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,065 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Disease Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

NCT00573443
View directory record Official record
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 15, 2026, 5:54 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT07287189
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
Interventions
SAT-3247, Placebo
Drug
Lead sponsor
Satellos Bioscience, Inc.
Industry
Eligibility
7 Years to 9 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

NCT05680818
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
Encaleret, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Active, not recruiting No phase listed Observational

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

NCT01278225
View directory record Official record
Conditions
Pain, Peripheral Neuropathy
Interventions
EEG biofeedback (BF) Group, Wait-List Control (WLC) Group, Follow UP Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

NCT00533091
View directory record Official record
Conditions
DERMATOMYOSITIS OR POLYMYOSITIS
Interventions
MEDI-545, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Whittier, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

NCT02450552
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ezogabine, Placebo
Drug
Lead sponsor
Brian Wainger
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 15, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurofibromatosis Type 1 Patient Registry

NCT01410006
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
2,391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 4 Interventional

Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training

NCT00101543
View directory record Official record
Conditions
Stroke
Interventions
Electrical Stimulation with Intramuscular Electrodes, Body Weight Supported Treadmill Training
Device · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Calorie Restriction With Leucine Supplementation

NCT01757340
View directory record Official record
Conditions
Obesity, Menopause, Osteoporosis, Sarcopenia
Interventions
Weight loss with normal protein and leucine intake, Weight loss with protein/leucine supplementation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 15, 2026, 5:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

NCT07221240
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Amisodin, Placebo
Drug · Other
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Feasibility and Clinically Application of Magnetic Resonance Fingerprinting

NCT02387840
View directory record Official record
Conditions
Neurofibromatosis Type 1, Brain Tumor, Glioma
Interventions
Magnetic Resonance Imaging, Magnetic Resonance Fingerprinting
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 15, 2026, 5:54 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vibration for Muscle Spasms After Spinal Cord Injury

NCT03598504
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Wearable EMG/Vibration device
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 15, 2026, 5:54 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348
View directory record Official record
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Interventions
Halneuron, Placebo, Halneuron (Open Label Extension)
Drug
Lead sponsor
Dogwood Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
25
States / cities
Sheffield, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Recruiting No phase listed Observational

Vascular Lab Resource (VLR) Biorepository

NCT05628948
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 15, 2026, 5:54 PM EDT
Withdrawn Not applicable Interventional

Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center

NCT01497678
View directory record Official record
Conditions
Traumatic Injury, Muscle Injury, Tendon Injury, Soft Tissue Injury, Extremity Injury
Interventions
Extracellular Matrix
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

NCT05695950
View directory record Official record
Conditions
Dermatomyositis
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Recruiting Phase 2 Interventional

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

NCT05010031
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

Virtual Cycling Environments for Persons With Parkinson Disease

NCT04804202
View directory record Official record
Conditions
Parkinson Disease
Interventions
Bicycling with and without virtual reality
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Newark, New Jersey • Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 15, 2026, 5:54 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise

NCT03540602
View directory record Official record
Conditions
Muscle Soreness
Interventions
Tart Cherry, Placebo Oral Capsule [CEBOCAP]
Dietary Supplement · Other
Lead sponsor
Jacksonville University
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation (TMS) for CRPS

NCT02067273
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 15, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.

NCT02654886
View directory record Official record
Conditions
Pompe Disease, Muscle Weakness
Interventions
Resistance Exercise Training
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
16 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 15, 2026, 5:54 PM EDT